<DOC>
	<DOCNO>NCT02876679</DOCNO>
	<brief_summary>The study design two arm randomize Phase II , multicenter trial compare cyclophosphamide anti-thymocyte globulin Graft-versus-Host Disease ( GVHD ) prophylaxis patient hematologic malignancy undergo reduced intensity conditioning hematopoietic stem cell transplantation .</brief_summary>
	<brief_title>Cyclophosphamide Versus Anti-thymocyte Globulin GVHD Prophylaxis After RIC Allo-SCT</brief_title>
	<detailed_description>Allogeneic stem cell transplantation ( allo-SCT ) well-established therapy different hematologic malignancy . Reduced-intensity conditioning ( RIC ) regimens decrease rate toxicity/mortality elderly patient , patient poor medical condition . GVHD prophylaxis remain challenge task allo-SCT . The Flu-ivBu combination widely use RIC regimen , endorse EMA since July 2014 . ATG combination cyclosporine-A ±mycophenolate mofetil backbone GVHD prophylaxis set . ATG prevent GVHD good efficacy , cost high toxicity profound immunosuppression , call effective therapy . The widely use RIC regimen France incorporate fludarabine ( Flu ) , intermediate dos IV-busulfan ( Bu ) anti-thymocyte globulin ( ATG ) . While use ATG prevent severe acute chronic GVHD allogeneic peripheral blood stem cell ( PBSC ) transplantation HLA-identical sibling unrelated donor , data suggest in-vivo T-cell depletion ATG RIC setting may induce high risk disease relapse . Also , ATG induce profound immune suppression increase incidence opportunistic infection , especially EBV-related complication ( relative risk=4.9 ; 95 % CI [ 1.1-21.0 ] ; P=0.03 ) . On hand , high-dose post-transplantation cyclophosphamide ( PTCy ) develop facilitate HLA-haploidentical allo-SCT use unmanipulated bone marrow ( BM ) cell . PTCy effective prevent acute chronic GVHD give capacity preferentially eliminate allo-reactive T cell preserve regulatory T cell , impact allogeneic immune reaction . Subsequently , efficacy PTCy sole GVHD prophylaxis myeloablative conditioning use BM also show . However , BM prefer source stem cell RIC allo-SCT , potential efficacy PTCy prevent GVHD use PBSCs ( frequently use source allogeneic cell worldwide ) debate . The advent PTCy therapy nowadays cut edge . Thus , potential efficacy ( cost-effectiveness ) PTCy GVHD prophylaxis may major ATG spar potential . A recent single centre phase 2 study ( n=49 ) suggest PTCy alone may prefer GVHD prophylaxis follow RIC transplant PBSCs . Indeed , A matched cohort analysis compare outcomes tacrolimus/methotrexate GVHD prophylaxis indicate high rate acute GVHD grade II IV ( 46 % versus 19 % ; hazard ratio [ HR ] , 2.8 ; P =0.02 ) treatment-related mortality ( HR , 3.3 ; P =0.035 ) bad overall survival ( HR , 1.9 ; P=0..04 ) post-CY . Interpretation non-randomized data complicate heterogeneity ( relate unrelated donor , BM PBSC stem cell source , different condition regimen ) , highlight need control randomized trial standardize setting . The ultimate goal Phase IIB study ass feasibility inform design subsequent phase III study . The present randomized trial design compare efficacy addition PTCy current standard care ATG Flu-Bu-based RIC regimen GVHD prophylaxis . The protocol use novel endpoint benchmarking intervention base composite primary endpoint GVHD-free , relapse-free survival measure freedom ongoing morbidity represent ideal outcome measure allo-SCT .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion Criteria : Patients age 18 65 year Presence hematologic malignancy reducedintensity condition alloSCT indicate ( eligibility criterion RIC alloSCT include least one follow parameter : ( ) patient age old 50 year ; ( ii ) heavily pretreated patient receive autologous hematopoietic SCT ( autoSCT ) 2 line chemotherapy alloSCT ; ( iii ) patient poor performance status significant medical comorbidities describe Sorror et al . Karnofsky index ≥ 70 % Availability sibling unrelated stemcell donor ( 10/10HLA match unrelated donor ) Efficient contraceptive method within 1 month woman 3 month men last dose treatment Written inform consent . Creatinine clearance le 30 mL/min Bilirubin aminotransferases 3X upper normal limit Cardiac ejection fraction le 40 % Pulmonary impairment &lt; 50 % lung carbon monoxide diffuse capacity ( DLCO ) Known hypersensitivity contraindication use posttransplant Cy ATG Any circumstance precludes use drug involve protocol Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hematopoietic Stem Cell</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Graft v Host Disease</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Anti-Thymocyte Globulin</keyword>
	<keyword>GVHD prophylaxis</keyword>
</DOC>